5-Oxoproline prevents doxorubicin-induced cardiotoxicity and tumor growth.

ABSTRACT:

Background

Doxorubicin (DOX), a classical chemotherapeutic agent, faces significant limitations because of its well-documented risk of inducing cardiotoxicity. Effective prevention of DOX-induced cardiotoxicity is urgently needed. Given that alterations in metabolic pathways have been observed in both cardiovascular diseases and cancer, targeting specific metabolic pathways may offer dual benefits by mitigating DOX-induced cardiotoxicity while simultaneously enhancing its antitumor efficacy.

Objectives

This study sought to explore the characteristic metabolic alterations associated with early DOX-induced cardiotoxicity and identify a therapeutic target that simultaneously inhibits cancer and protects the myocardium.

Methods

Metabolomic and transcriptomic analyses were

SUBMITTER: Guo X 

PROVIDER: S-EPMC12274918 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature